Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AA10021: Phase II data

In a double-blind, dose-ranging, U.S. and Canadian Phase II trial in 87 patients, DDP225 met

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE